Nuclear medicine imaging allows doctors to see how organs and tissues function by tracking tiny amounts of radioactive material inside the body. Unlike many imaging techniques that primarily show anatomy, such as the size and shape of organs, nuclear medicine can reveal changes in metabolism, blood flow, and other biological processes that may signal disease before obvious structural changes appear.
The key is a substance called a radiotracer, which combines a radioactive atom with a molecule that travels to a particular tissue or participates in a specific process in the body. As the radioactive atom releases energy, specialized cameras detect that energy and use it to create images. Doctors can then examine patterns of activity to help identify disease, assess how far it has progressed, monitor treatment, or determine whether a therapy is working.
Nuclear medicine is used to investigate many conditions, including cancer, heart disease, thyroid disorders, bone abnormalities, and certain neurological conditions. Although the technique involves radiation, the amount used for diagnostic imaging is carefully selected to provide useful information while limiting exposure.
What makes nuclear medicine different from other medical imaging?
Medical imaging methods differ in what they measure. X-rays and computed tomography (CT) primarily reveal differences in the way tissues absorb X-ray radiation. Magnetic resonance imaging (MRI) uses magnetic fields and radio waves to produce detailed images of internal structures. Ultrasound uses sound waves to visualize tissues and movement.
Nuclear medicine takes a different approach. Instead of relying mainly on the body’s physical structure, it measures signals from radioactive tracers administered to a patient. These signals indicate where the tracer travels, how much accumulates in different tissues, and how its distribution changes over time.
This distinction matters because disease often changes the way cells behave before it changes the way an organ looks. Cancer cells may use glucose differently from surrounding cells. A region of the heart may receive too little blood. The thyroid gland may produce too much or too little hormone. A nuclear medicine scan can reveal aspects of these processes that a structural image alone might not show.
The methods are complementary rather than interchangeable. A CT scan may show the precise location and size of a mass, while a nuclear medicine scan may indicate whether the tissue is unusually active. Combining the two can help doctors interpret an abnormal finding more accurately.
However, increased or decreased tracer activity does not automatically establish a diagnosis. Normal tissues can show high activity, and inflammation or other noncancerous conditions can produce abnormal patterns. Doctors interpret the images alongside symptoms, medical history, laboratory results, and other imaging findings.
How radioactive tracers work inside the body
A radiotracer contains two essential components: a radioactive isotope and a molecule or compound that helps determine where the tracer goes.
An isotope is a form of an element with a particular number of neutrons in its atomic nucleus. Some isotopes are unstable and release energy as they transform into more stable forms. These are called radioactive isotopes. In nuclear medicine, carefully selected isotopes provide detectable signals while remaining useful for a limited period.
The nonradioactive part of a tracer influences its behavior in the body. Depending on the tracer, it may resemble a naturally occurring substance, bind to a particular protein, attach to a cell receptor, or participate in a chemical process. Because tissues differ in their blood supply, metabolism, and molecular characteristics, tracers can accumulate in different amounts in different locations.
Consider a tracer designed to follow glucose metabolism. After it enters the bloodstream, cells take it up through mechanisms associated with glucose transport. A commonly used PET tracer, fluorine-18 fluorodeoxyglucose (FDG), resembles glucose but behaves differently after entering cells. Its radioactive signal can help reveal areas of elevated glucose use.
Many cancers have high glucose uptake, so FDG can help doctors locate and assess certain tumors. But the tracer is not exclusive to cancer. The brain normally uses substantial amounts of glucose, and activated immune cells can also take up FDG. These normal and disease-related patterns must be considered when interpreting a scan.
Other tracers follow entirely different biological pathways. Some concentrate in bone during mineral turnover. Others interact with receptors in particular cells or accumulate in tissues involved in hormone production. The tracer’s chemistry and the body’s biology together determine what the resulting image can reveal.
The radioactive isotope supplies the signal, while the tracer’s biological behavior supplies much of the medical meaning.
How a nuclear medicine scan produces an image
A typical diagnostic scan involves several stages: preparing the patient, administering the tracer, allowing it to distribute through the body, detecting its emissions, and reconstructing the collected data into images.
The tracer is commonly given through an injection into a vein, although some studies use a swallowed preparation or an inhaled substance. The route depends on the tracer and the organ or process being examined.
After administration, the patient may need to wait while the tracer reaches its target tissues. This interval can range from relatively short periods to longer waits, depending on how the substance moves and how the body processes it. Some scans also require specific preparation, such as fasting or temporarily avoiding certain medications, when appropriate for the examination.
During imaging, a detector records energy emitted by the radioactive isotope. Different nuclear medicine techniques use different types of detectors because radioactive isotopes release energy in different ways.
In single-photon emission computed tomography (SPECT), the tracer emits gamma rays that can be detected directly by a gamma camera. The camera rotates around the patient, collecting measurements from multiple angles. A computer reconstructs these measurements into three-dimensional images of tracer distribution.
Positron emission tomography (PET) detects a different signal. Certain radioactive isotopes emit positrons, which are positively charged particles with the same mass as electrons. After traveling a short distance through tissue, a positron usually encounters an electron. The two particles annihilate each other, producing two gamma-ray photons that travel in nearly opposite directions.
PET scanners detect pairs of photons arriving at opposite sides of the detector ring within a very short time interval. This coincidence detection helps identify where the annihilation event occurred. By collecting many such events, the scanner builds a three-dimensional map of tracer distribution.
Both PET and SPECT can produce cross-sectional and three-dimensional images. The resulting images may show the relative intensity of tracer activity across tissues, and some examinations also estimate tracer concentration quantitatively.
The scanner does not directly photograph individual cells or display every chemical reaction in real time. Instead, it measures radioactive emissions and uses mathematical reconstruction to infer where the tracer is located and how it is distributed. The interpretation depends on both the quality of those measurements and an understanding of the tracer’s behavior.
What nuclear medicine can reveal about disease
Nuclear medicine is particularly valuable when a disease changes biological activity in ways that can be measured with a suitable tracer. Different examinations are designed to answer different clinical questions.
Cancer detection and treatment assessment
PET imaging with FDG is widely used in the evaluation of many cancers. Because some tumors consume glucose rapidly, they may appear as areas of increased tracer uptake. This can help doctors identify suspicious lesions, assess whether cancer has spread to other parts of the body, select sites for biopsy, and evaluate response to treatment.
PET is often combined with CT in a single examination. The PET component reveals patterns of metabolic activity, while the CT component supplies detailed anatomical information. Together, they can help doctors determine whether an area of increased activity corresponds to a lymph node, organ, bone, or other structure.
Not all cancers behave alike. Some tumors have relatively low FDG uptake, and small lesions may be difficult to detect. Inflammation, infection, and normal physiological activity can also produce increased uptake. Other PET tracers target different biological features, such as specific receptors or proteins, and may be more informative for particular cancers.
After treatment, changes in tracer uptake can help assess whether a tumor’s activity has decreased. However, timing matters. Treatment-related inflammation can temporarily increase tracer uptake, while certain tumors may remain visible on structural imaging even when their biological activity has fallen. Doctors therefore interpret follow-up scans in the context of the treatment and the disease being monitored.
Heart disease and blood flow
Nuclear cardiology uses radioactive tracers to assess blood flow to the heart muscle and, in some examinations, the muscle’s ability to function.
During myocardial perfusion imaging, a tracer is administered and its distribution in the heart muscle is measured. Doctors may obtain images when the heart is at rest and when it is under stress, induced by exercise or medication.
If a region of heart muscle receives less blood during stress than expected, it may indicate reduced blood supply caused by narrowed coronary arteries. If an area shows reduced tracer uptake during both stress and rest, the finding may reflect scar tissue from a previous heart attack, although other explanations are possible.
These patterns help doctors assess whether coronary artery disease is limiting blood flow and whether further evaluation or treatment may be needed. Some nuclear medicine techniques also estimate how effectively the heart pumps blood.
The test does not simply measure the degree of arterial narrowing. It evaluates the physiological consequences of blood flow through the coronary circulation, providing information that complements anatomical tests.
Bone disease and skeletal abnormalities
Bone scans use tracers that accumulate in association with bone formation and mineral turnover. Their distribution reflects the activity of the skeleton rather than bone structure alone.
Areas of increased uptake may occur where bone is repairing itself or undergoing unusually active remodeling. Possible causes include fractures, arthritis, infection, and some bone tumors. Certain cancers that spread to bone can also produce abnormal patterns.
Because several conditions can cause similar findings, a bone scan may identify an area requiring further investigation without determining its exact cause. X-rays, CT, MRI, laboratory tests, or biopsy may be needed to clarify the diagnosis.
Bone imaging is also useful when symptoms or other findings suggest a skeletal problem that may not be limited to a single location. A whole-body scan can reveal patterns of abnormal activity across many bones in one examination.
Thyroid disorders
The thyroid gland uses iodine to produce hormones that help regulate metabolism. Nuclear medicine takes advantage of this biological property through tests that measure how the gland takes up iodine or an appropriate iodine-like tracer.
Thyroid uptake studies can help distinguish different causes of abnormal thyroid hormone production. In some cases, imaging reveals areas of the gland that take up more tracer than surrounding tissue, while other areas show reduced uptake.
A thyroid scan can also help evaluate nodules and certain other thyroid conditions. Its usefulness depends on the clinical question, and ultrasound, hormone measurements, and other tests often provide complementary information.
Radioactive iodine is also used therapeutically in selected thyroid disorders. In that setting, the radioactive material is chosen not merely to create an image but to deliver radiation to thyroid tissue.
Brain and nervous system disorders
The brain’s activity depends on blood flow, glucose use, and the behavior of specific molecular systems. PET and SPECT can measure selected aspects of these processes, providing information that structural imaging alone may not capture.
Some brain scans assess regional blood flow or glucose metabolism. Others use tracers that bind to particular receptors, transporters, or proteins associated with a neurological condition.
These techniques can support the evaluation of certain seizure disorders, movement disorders, and cognitive conditions. They may help identify patterns consistent with a disease or guide decisions about further testing.
A brain scan rarely provides a complete explanation on its own. Similar patterns can occur in different disorders, and interpretation depends on the patient’s symptoms, examination, medical history, and other test results. Not every neurological condition requires nuclear medicine imaging, and the choice of test depends on the question being investigated.
Why the timing and amount of tracer matter
A nuclear medicine image is influenced not only by where a tracer travels but also by when the scan is performed.
Immediately after administration, a tracer may still be moving through the bloodstream. Over time, it may accumulate in target tissues, enter cells, bind to specific molecules, or leave the body. The interval between administration and imaging is selected to make the relevant biological pattern easier to measure.
For example, a tracer that reflects blood flow may be imaged on a different schedule from one that requires time to enter cells or bind to a target. Imaging too early or too late can change the contrast between tissues and affect how the results are interpreted.
The amount of radioactivity administered also matters. Too little may produce insufficient signal for reliable imaging, while more activity increases radiation exposure. Medical teams select a dose appropriate to the examination, the equipment, and the patient. In children, doses are generally adjusted for body size and clinical needs.
Radioactive tracers also lose activity over time through radioactive decay. Each isotope has a characteristic half-life, the time required for half of the radioactive nuclei in a sample to decay. After one half-life, half the original radioactive nuclei remain; after another, half of that remaining amount decays.
Physical decay is only part of what happens inside the body. The tracer may also be removed through the kidneys, urine, digestive system, or other biological pathways. The combined effects of radioactive decay and biological elimination determine how quickly the radioactive material leaves the body or ceases to produce a significant signal.
These characteristics help medical teams choose tracers that remain detectable long enough to obtain useful images without leaving unnecessary radioactivity in the body.
How safe is nuclear medicine imaging?
Nuclear medicine uses ionizing radiation, which carries enough energy to remove electrons from atoms and molecules. At sufficiently high exposures, ionizing radiation can damage cells and tissues. Medical imaging therefore involves balancing the expected diagnostic benefit against the potential risks of radiation exposure.
For a medically justified examination, the tracer and administered activity are selected to provide useful information while keeping exposure as low as reasonably achievable. The radiation dose varies considerably with the isotope, the amount administered, the type of scan, and the patient’s physiology.
The risk from a single diagnostic examination is generally low, but it is not zero. Because radiation-related risk can accumulate with exposure, clinicians consider previous imaging, alternative tests, and whether the expected information is likely to affect care. Nuclear medicine is not automatically the best option simply because it can detect a biological process.
The radioactive material is often eliminated through normal bodily processes, although the timing depends on the tracer. Patients may receive instructions to drink fluids, urinate regularly, or take other simple precautions after certain examinations. These instructions help reduce the time radioactive material remains in the body or limit avoidable exposure to others.
Pregnancy requires particular consideration because a developing fetus can be more sensitive to radiation. Patients who are pregnant or might be pregnant should tell their medical team before the examination. Breastfeeding instructions vary according to the specific tracer; some examinations require temporary interruption, while others do not. Patients should follow the instructions provided for their particular study rather than assume that all radioactive tracers behave the same way.
Allergic reactions to radiotracers are possible but uncommon. Other risks may relate to the administration method, associated medications, or the underlying condition rather than to the radioactive material itself. The medical team can explain the relevant risks and precautions for an individual examination.
What nuclear medicine can and cannot tell doctors
Nuclear medicine can reveal functional abnormalities that are difficult to detect with anatomical imaging alone. It can also survey large areas of the body and measure changes in tracer uptake over time, making it useful for evaluating disease and monitoring treatment.
Its limitations are equally important. A scan records the distribution of a particular tracer, not disease in the abstract. If the tracer does not target a feature of the condition being investigated, the scan may be uninformative. Some lesions are too small to resolve clearly, and normal activity can obscure nearby abnormalities.
Images also have finite spatial resolution. A scanner cannot reliably distinguish structures smaller than its practical detection limits, and apparent tracer uptake depends on factors such as tissue movement, blood flow, image reconstruction, and the amount of surrounding activity. Quantitative measurements can be affected by technical and biological variables, so they must be interpreted carefully.
An abnormal scan is therefore evidence to be considered, not necessarily a final diagnosis. Increased uptake may indicate cancer, inflammation, normal organ function, or another process, depending on the tracer and location. Reduced uptake may reflect impaired blood flow, loss of functioning tissue, or a different biological change.
Doctors integrate nuclear medicine findings with the patient’s clinical picture and other diagnostic information. Sometimes a scan provides a clear answer; in other cases, additional imaging, laboratory tests, follow-up, or tissue sampling is needed.
When radioactive tracers are used to treat disease
Although nuclear medicine is best known for diagnostic imaging, the same underlying principle can also be used to deliver treatment. This approach is called radionuclide therapy or targeted radionuclide therapy.
In diagnostic imaging, tracers are selected to emit radiation that detectors can measure efficiently. In therapy, radioactive substances are chosen to deliver enough energy to damage diseased cells while limiting injury to surrounding healthy tissue. The therapeutic substance may travel to a target because of its chemical properties, its interaction with a receptor, or its uptake by a particular organ.
Radioactive iodine treatment for certain thyroid conditions is one established example. Thyroid cells naturally take up iodine, allowing radioactive iodine to deliver radiation to thyroid tissue. Other targeted treatments use radioactive substances attached to molecules that recognize features of certain cancer cells or their surroundings.
Some therapeutic agents emit particles, such as beta particles or alpha particles, that deposit energy over short distances in tissue. This can damage cellular structures, including DNA, and prevent targeted cells from continuing to divide or survive. The range and biological effects of the emitted radiation depend on the isotope and the type of particle.
Treatment selection requires careful consideration of whether the target is present, how widely the therapeutic substance will distribute, and whether normal organs are likely to receive harmful doses. Patients may undergo imaging or other assessments to determine whether a particular therapy is appropriate and to evaluate its effects.
Diagnostic nuclear medicine and radionuclide therapy thus apply the same central idea in different ways: radioactive substances can reveal biological processes or deliver energy to selected tissues. In both cases, the value of the technique depends on matching the properties of the radioactive substance to a specific medical purpose.
The role of nuclear medicine in modern diagnosis
Nuclear medicine provides a way to investigate the body’s internal chemistry and physiology without requiring surgery or directly sampling every suspicious tissue. By pairing radioactive isotopes with molecules that follow particular biological pathways, clinicians can turn otherwise invisible processes into measurable signals.
These scans are most powerful when their findings answer a specific clinical question. They can help distinguish functioning tissue from damaged tissue, identify patterns of abnormal metabolism, assess blood flow, and reveal whether a disease changes after treatment. When combined with CT, MRI, laboratory testing, and clinical examination, they contribute information that no single method can provide on its own.
The central principle is straightforward: the radioactive atom makes the tracer detectable, while the tracer’s behavior reveals something about the tissue in which it accumulates. Understanding both parts explains why nuclear medicine can help doctors find disease, why its results require careful interpretation, and why the same technology can sometimes be used to treat the conditions it helps identify.